Fauna Bio has raised $9.0M in total across 1 funding round.
Fauna Bio's investors include Bija Ventures, Lifeforce Capital.
# Fauna Bio: AI-Powered Drug Discovery from Evolutionary Biology
Fauna Bio is a biotechnology company, not a technology company, though it employs advanced AI and computational tools as core infrastructure. Founded in 2018 and headquartered in Emeryville, California, Fauna Bio develops novel drug targets by analyzing genetic data from "extreme mammals"—species with evolved resistance to conditions like hibernation, cancer, fibrosis, and metabolic disorders[1][2]. The company serves pharmaceutical partners seeking validated drug targets, solving a critical bottleneck in drug discovery: identifying the right targets before expensive clinical development begins[4].
The company's mission centers on translating 100 million years of evolutionary optimization into human therapeutics[2]. Rather than requiring AI-native biotech companies to design and execute millions of wet lab experiments costing over $100 million, Fauna Bio leverages nature's experiments, achieving in-vivo validation with less than $500,000 in discovery costs[4]. This efficiency advantage has already attracted major pharma validation: in December 2023, Eli Lilly committed to a multi-year, $494 million collaboration using Fauna's platform for obesity drug discovery[2].
Fauna Bio was founded in 2018 by a team with deep expertise in comparative genomics and evolutionary biology[8]. CEO and co-founder Ashley Zehnder holds a PhD in Cancer Biology from Stanford and is a board-certified avian veterinarian with translational research experience[5]. This combination of veterinary medicine and cancer biology directly informed the company's insight: studying disease-resistant animals could unlock human therapeutic mechanisms.
The founding insight emerged from recognizing that blockbuster drugs—ACE inhibitors, GLP-1 agonists, and PCSK9 inhibitors—originated from studying diverse species[2]. Fauna Bio became the first company to systematize this approach at scale, combining comparative genomics with AI to create a repeatable discovery engine. Early traction came through assembling an unparalleled biobank: over 46 billion sequence reads, thousands of omics datasets, and whole-genome alignments across 240 mammals through partnership with the Zoonomia Consortium[1][4].
Fauna Bio operates at the intersection of three powerful trends: AI-driven drug discovery, comparative genomics, and the shift toward data-efficient biotech. The company rides the wave of computational biology becoming mainstream, where machine learning can synthesize complex biological datasets faster than human researchers.
The timing is critical. Traditional drug discovery faces a productivity crisis—the cost per approved drug has risen exponentially while approval timelines have lengthened. Fauna Bio's approach addresses this by reducing the number of failed targets that reach expensive clinical trials. By leveraging evolutionary data, the company sidesteps the need for massive experimental campaigns, making drug discovery more capital-efficient and accessible to smaller biotech firms.
Within the broader biotech ecosystem, Fauna Bio influences how companies think about target validation. Rather than treating animal models as afterthoughts, the company positions them as primary discovery engines. This reframes comparative biology from a niche academic discipline into a competitive advantage for pharma partnerships.
Fauna Bio is positioned to become a critical infrastructure layer in drug discovery, similar to how sequencing platforms transformed genomics. As the company expands Fauna Brain's capabilities across new disease areas—currently spanning neurodegeneration, heart failure, kidney disease, GI disease, inflammation, fibrosis, and tissue regeneration[4]—it will likely attract additional pharma partnerships and potentially expand into therapeutic areas with $60+ billion market opportunities[2].
The company's trajectory depends on two factors: continued validation of AI-identified targets in clinical development, and the ability to scale its biobank and computational platform faster than competitors can replicate it. With only about 20 employees currently, Fauna Bio remains capital-efficient, but scaling will require investment in both talent and data infrastructure[6].
The broader implication: if Fauna Bio successfully demonstrates that evolutionary biology + AI can consistently identify better drug targets than traditional approaches, it could fundamentally reshape how the pharmaceutical industry approaches early-stage discovery, shifting investment away from brute-force experimental screening toward intelligent data synthesis.
Fauna Bio has raised $9.0M across 1 funding round. Most recently, it raised $9.0M Seed in September 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2021 | $9.0M Seed | Bija Ventures, Lifeforce Capital |
